{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:03:47Z","timestamp":1773342227886,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Youth Foundation of Zhongshan Hospital, Fudan University","award":["2021ZSQN18"],"award-info":[{"award-number":["2021ZSQN18"]}]},{"name":"Project of Hospital Pharmacy Committee of the Chinese Pharmaceutical Association","award":["CPA-Z05-ZC-2022-002"],"award-info":[{"award-number":["CPA-Z05-ZC-2022-002"]}]},{"name":"Project of Clinical Key Subject Construction of Shanghai","award":["shslczdzk06504"],"award-info":[{"award-number":["shslczdzk06504"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00228-026-04004-y","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:16:43Z","timestamp":1770614203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bleeding risk of rivaroxaban and edoxaban with and without amiodarone in atrial fibrillation patients: a prospective cohort study"],"prefix":"10.1007","volume":"82","author":[{"given":"Zi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"4004_CR1","doi-asserted-by":"publisher","unstructured":"Jos\u00e9 AJ, Mina KC, Anastasia LA et al (2023) ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 149(1):149(1):e1\u2013e156. https:\/\/doi.org\/10.1161\/cir.0000000000001193","DOI":"10.1161\/cir.0000000000001193"},{"key":"4004_CR2","doi-asserted-by":"publisher","unstructured":"Isabelle CVG, Michiel R, Karina VB et al (2024) ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J 45(36):3314\u20133414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"4004_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae298","author":"M Rienstra","year":"2024","unstructured":"Rienstra M, Tzeis S, Bunting KV (2024) Spotlight on the 2024 ESC\/EACTS management of atrial fibrillation guidelines: 10 novel key aspects. Europace\u00a026(12):euae298.\u00a0https:\/\/doi.org\/10.1093\/europace\/euae298","journal-title":"Europace"},{"key":"4004_CR4","doi-asserted-by":"publisher","unstructured":"Mark SL, Robert PG, Christian TR et al (2017) Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial (Effective anticoagulation with factor Xa next generation in atrial Fibrillation-Thrombolysis in myocardial infarction 48). Circ Arrhythm Electrophysiol 10(1):e004267. https:\/\/doi.org\/10.1161\/circep.116.004267","DOI":"10.1161\/circep.116.004267"},{"key":"4004_CR5","doi-asserted-by":"publisher","unstructured":"Robert PG, Christian TR, Eugene B et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","DOI":"10.1056\/NEJMoa1310907"},{"key":"4004_CR6","doi-asserted-by":"publisher","unstructured":"Chun-Li VC-CW, Yu-Chang W (2024) Bleeding associated with antiarrhythmic drugs in patients with atrial fibrillation using direct oral anticoagulants: A nationwide population cohort study. J Am Heart Assoc 13(21):e033513. https:\/\/doi.org\/10.1161\/jaha.123.033513","DOI":"10.1161\/jaha.123.033513"},{"key":"4004_CR7","doi-asserted-by":"publisher","unstructured":"Paolo G, Antonio DV, Claudio P et al (2019) Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med 65:51\u201357. https:\/\/doi.org\/10.1016\/j.ejim.2019.05.002","DOI":"10.1016\/j.ejim.2019.05.002"},{"key":"4004_CR8","doi-asserted-by":"publisher","unstructured":"Eleanor Jing Yi C, Janice Jia Ni G, Yanjun H et al (2017) Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies. Drug Metab Dispos 45(3):260\u2013268. https:\/\/doi.org\/10.1124\/dmd.116.073890","DOI":"10.1124\/dmd.116.073890"},{"key":"4004_CR9","doi-asserted-by":"publisher","unstructured":"Eleanor Jing Yi C, Janice Jia Ni G, Yanjun H, Pipin K (2018) Eric Chun Yong C. Rivaroxaban with and without Amiodarone in renal impairment. J Am Coll Cardiol 71(12):1395\u20131397. https:\/\/doi.org\/10.1016\/j.jacc.2018.01.044","DOI":"10.1016\/j.jacc.2018.01.044"},{"key":"4004_CR10","doi-asserted-by":"publisher","unstructured":"Maxim G, Laura C, Andreas C et al (2023) Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 9(8):722\u2013730. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad070","DOI":"10.1093\/ehjcvp\/pvad070"},{"key":"4004_CR11","doi-asserted-by":"publisher","unstructured":"R P G JS (2015) Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 36(33):2239\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehv201","DOI":"10.1093\/eurheartj\/ehv201"},{"key":"4004_CR12","doi-asserted-by":"publisher","unstructured":"Rillig A, Borof K, Breithardt G, et al (2022) Early rhythm control in patients with atrial fibrillation and high comorbidity burden. Circulation 146(11):836\u2013847. https:\/\/doi.org\/10.1161\/circulationaha.122.060274","DOI":"10.1161\/circulationaha.122.060274"},{"key":"4004_CR13","doi-asserted-by":"publisher","unstructured":"John A, Gerald C, Suneet VN (2022) The increasing role of rhythm control in patients with atrial fibrillation: JACC State-of-the-Art review. J Am Coll Cardiol 79(19):1932\u20131948. https:\/\/doi.org\/10.1016\/j.jacc.2022.03.337","DOI":"10.1016\/j.jacc.2022.03.337"},{"key":"4004_CR14","doi-asserted-by":"publisher","unstructured":"Jeanne M, Hamim Z, Nobuko M et al (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13(5):331\u201342. https:\/\/doi.org\/10.1007\/s40256-013-0029-0","DOI":"10.1007\/s40256-013-0029-0"},{"issue":"9","key":"4004_CR15","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N et al (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study \u2013. Circ J 76(9):2104\u20132111","journal-title":"Circ J"},{"issue":"5","key":"4004_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/MNH.0000000000000634","volume":"29","author":"TA Mavrakanas","year":"2020","unstructured":"Mavrakanas TA, Charytan DM, Winkelmayer WC (2020) Direct oral anticoagulants in chronic kidney disease: an update. Curr Opin Nephrol Hypertens 29(5):489\u2013496. https:\/\/doi.org\/10.1097\/MNH.0000000000000634","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"22","key":"4004_CR17","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"4004_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad288","author":"Y-H Chan","year":"2023","unstructured":"Chan Y-H, Chan C-Y, Chen S-W, Chao T-F, Lip GYH (2023) Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies. Europace 25(10):euad288. https:\/\/doi.org\/10.1093\/europace\/euad288","journal-title":"Europace"},{"key":"4004_CR19","doi-asserted-by":"publisher","unstructured":"Konrad MA (2013) Comments on \u2018KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease\u2019. Kidney Int 84(3):622\u20133. https:\/\/doi.org\/10.1038\/ki.2013.243","DOI":"10.1038\/ki.2013.243"},{"issue":"11","key":"4004_CR20","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemostasis 13(11):2119\u20132126","journal-title":"J Thromb Haemostasis: JTH"},{"issue":"12","key":"4004_CR21","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/europace\/euaa239","volume":"22","author":"G Stabile","year":"2020","unstructured":"Stabile G, Iacopino S, Verlato R et al (2020) Predictive role of early recurrence of atrial fibrillation after cryoballoon ablation. EP Europace 22(12):1798\u20131804. https:\/\/doi.org\/10.1093\/europace\/euaa239","journal-title":"EP Europace"},{"key":"4004_CR22","doi-asserted-by":"publisher","unstructured":"Anthony PC, Hwanhee H, Stuart JC et al Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022;145(4):242\u2013255. https:\/\/doi.org\/10.1161\/circulationaha.121.056355","DOI":"10.1161\/circulationaha.121.056355"},{"key":"4004_CR23","doi-asserted-by":"publisher","unstructured":"Manesh RP, Kenneth WM, Jyotsna G et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa1009638","DOI":"10.1056\/NEJMoa1009638"},{"key":"4004_CR24","doi-asserted-by":"publisher","unstructured":"Cecilia M, Renato B, Daniel DL (2016) Non-major bleeding with Apixaban versus warfarin in patients with atrial fibrillation. Heart 103(8):623\u2013628. https:\/\/doi.org\/10.1136\/heartjnl-2016-309901","DOI":"10.1136\/heartjnl-2016-309901"},{"issue":"13","key":"4004_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJM200003303421302","volume":"342","author":"D Roy","year":"2000","unstructured":"Roy D, Talajic M, Dorian P et al (2000) Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342(13):913\u2013920","journal-title":"N Engl J Med"},{"issue":"3","key":"4004_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jtcvs.2015.07.034","volume":"151","author":"N Ad","year":"2015","unstructured":"Ad N, Holmes SD, Shuman DJ, Pritchard G, Miller CE (2015) Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. J Thorac Cardiovasc Surg 151(3):798\u2013803. https:\/\/doi.org\/10.1016\/j.jtcvs.2015.07.034","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10480","key":"4004_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","volume":"405","author":"F Couturaud","year":"2025","unstructured":"Couturaud F, Schmidt J, Sanchez O et al (2025) Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet 405(10480):725\u2013735. https:\/\/doi.org\/10.1016\/S0140-6736(24)02842-3","journal-title":"Lancet"},{"issue":"5","key":"4004_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jacc.2018.04.084","volume":"72","author":"Y-C Lin","year":"2018","unstructured":"Lin Y-C, Chien S-C, Hsieh Y-C et al (2018) Effectiveness and safety of standard- and low-dose rivaroxaban in Asians with atrial fibrillation. J Am Coll Cardiol 72(5):477\u2013485. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.084","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"4004_CR29","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1177\/1060028021995201","volume":"55","author":"H Whittemore","year":"2021","unstructured":"Whittemore H, Posen AK, Hellenbart EL, Groo V, Wenzler E, Tilton JJ (2021) The impact of body weight and renal function on the risk of bleeding with direct oral anticoagulants in atrial fibrillation. Ann Pharmacother 55(11):1309\u20131317. https:\/\/doi.org\/10.1177\/1060028021995201","journal-title":"Ann Pharmacother"},{"issue":"6","key":"4004_CR30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40262-022-01108-3","volume":"61","author":"F Zhang","year":"2022","unstructured":"Zhang F, Chen X, Wu T et al (2022) Population pharmacokinetics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation: a prospective multicenter study. Clin Pharmacokinet 61(6):881\u2013893. https:\/\/doi.org\/10.1007\/s40262-022-01108-3","journal-title":"Clin Pharmacokinet"},{"key":"4004_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020588","author":"X-Q Liu","year":"2023","unstructured":"Liu X-Q, Li Z-R, Wang C-Y, Chen Y-T, Jiao Z (2023) Is a lower dose of rivaroxaban required for Asians? A systematic review of a population pharmacokinetics and pharmacodynamics analysis of rivaroxaban. Pharmaceutics 15(2):588. https:\/\/doi.org\/10.3390\/pharmaceutics15020588","journal-title":"Pharmaceutics"},{"issue":"8","key":"4004_CR32","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e72","volume":"39","author":"JY Kim","year":"2024","unstructured":"Kim JY, Kim J, Park S-J et al (2024) Comparison of high- and low-dose rivaroxaban regimens in elderly East Asian patients with atrial fibrillation. J Korean Med Sci 39(8):e72. https:\/\/doi.org\/10.3346\/jkms.2024.39.e72","journal-title":"J Korean Med Sci"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04004-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:52:57Z","timestamp":1773309177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04004-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4004"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04004-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the ethics committee of Zhongshan Hospital, Fudan University. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}